Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Biogen Q1 quick-take...Spinraza beat...Other stuff fine...stock should be up at open — Mizuho (276.86)Mizuho notes BIIB just reported 1Q17 earnings. The notable takeaway from the print is that Spinraza beat consensus by a wide margin ($46MM in the US vs buyside consensus of $16MM and sellside consensus of $13-16MM). BIIB didn't quantify how much of this number is inventory, but calls out in the slides «some natural inventory build», so they suspect even stripping inventory out, Spinraza still beat consensus. The rest of the quarter looks fine. No update to guidance (recall, BIIB typically doesn't update guidance on the 1Q call, and typically waits for 2Q). They expect the stock to trade up on the open.<br/> <br/> BIIB +4.5% premarket; Spinraza developer Ionis (<strong>IONS</strong>) +6%.</td> </tr></table>"